BARC.L
$393.75
Barclays PLC provides various financial services in the United Kingdom, Europe, the Americas, Africa, the Middle East, and Asia.
Historical Price
Peer Comparison
Whystock Valuation Model
Fundamentals
Barclays PLC provides various financial services in the United Kingdom, Europe, the Americas, Africa, the Middle East, and Asia. The company operates through Barclays UK; Barclays UK Corporate Bank; Barclays Private Bank and Wealth Management; Barcla...
Recent News
Financial Services Roundup: Market Talk
Find insight on UniCredit, Perpetual and more in the latest Market Talks covering Financial Services.
Goldman Sachs Maintains a Buy on Barclays PLC (BCS), Raises PT
Barclays PLC (NYSE:BCS) is one of the Most Undervalued Long Term Stocks to Buy According to Analysts. On March 11, analyst Chris Hallam of Goldman Sachs maintained a Buy rating on Barclays PLC (NYSE:BCS) and raised the price target from p550 to p590. The analyst said in a research note that he sees Barclays and […]
Barclays Private Bank Leadership Moves And What They Could Mean For Investors
Barclays (LSE:BARC) has appointed Adrish Ghosh as Head of Private Bank for India. The bank has also named Olivier Franceschelli as CEO of Private Bank Monaco. These leadership changes affect Barclays' wealth management operations in key international markets. For you as an investor, these appointments sit within Barclays' broader focus on private banking and wealth management, areas where client relationships and local expertise are central. India and Monaco are both important hubs for high...
How The JetBlue Airways (JBLU) Story Is Shifting With Fuel Risks And Mixed Analyst Views
JetBlue Airways now carries an updated fair value estimate of US$4.93 per share, compared with the prior US$4.86, giving investors a fresh reference point for the stock. This adjustment comes as analysts split between US$3.50 to US$4 targets on cost worries and US$5 to US$7 targets tied to views that the current price already reflects considerable execution risk. As you read on, you will see how these moving targets shape the evolving story around JetBlue and what to watch next in the data...
4D Molecular Therapeutics Maps Phase 3 4D-150 Timeline, DME Expansion in Barclays Conference Talk
Executives from 4D Molecular Therapeutics (NASDAQ:FDMT) outlined the company’s gene therapy platform, clinical progress, and commercialization plans during a Barclays analyst discussion in Miami, highlighting its lead retinal program 4D-150 and an earlier-stage effort in cystic fibrosis. Company ov